Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Obstetrics and Gynecology
Volume 2015 (2015), Article ID 123408, 6 pages
http://dx.doi.org/10.1155/2015/123408
Case Report

Response to Plasmapheresis Measured by Angiogenic Factors in a Woman with Antiphospholipid Syndrome in Pregnancy

1Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
2Department of Nephrology, Medical University of Graz, Graz, Austria

Received 16 March 2015; Accepted 8 July 2015

Academic Editor: Eliezer Shalev

Copyright © 2015 Karoline Mayer-Pickel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Miyakis, M. D. Lockshin, T. Atsumi et al., “International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS),” Journal of Thrombosis and Haemostasis, vol. 4, no. 2, pp. 295–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. C. W. Redman and I. L. Sargent, “Latest advances in understanding preeclampsia,” Science, vol. 308, no. 5728, pp. 1592–1594, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. R. J. Levine, S. E. Maynard, C. Qian et al., “Circulating angiogenic factors and the risk of preeclampsia,” The New England Journal of Medicine, vol. 350, no. 7, pp. 672–683, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Girardi, J. Berman, P. Redecha et al., “Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome,” Journal of Clinical Investigation, vol. 112, no. 11, pp. 1644–1654, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. V. M. Holers, G. Girardi, L. Mo et al., “Complement C3 activation is required for antiphospholipid antibody-induced fetal loss,” The Journal of Experimental Medicine, vol. 195, no. 2, pp. 211–220, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Alijotas-Reig, “Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management,” Lupus, vol. 22, no. 1, pp. 6–17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Ornaghi and M. J. Paidas, “Upcoming drugs for the treatment of preeclampsia in pregnant women,” Expert Review of Clinical Pharmacology, vol. 7, no. 5, pp. 599–603, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Thadhani, T. Kisner, H. Hagmann et al., “Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia,” Circulation, vol. 124, no. 8, pp. 940–950, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Wang, A. K. Walli, A. Schulze et al., “Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia,” Transfusion and Apheresis Science, vol. 35, no. 2, pp. 103–110, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Shenkman and Y. Einav, “Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification,” Autoimmunity Reviews, vol. 13, no. 4-5, pp. 584–586, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Fyfe-Brown, G. Clarke, K. Nerenberg, S. Chandra, and V. Jain, “Management of pregnancy-associated thrombotic thrombocytopenia purpura,” American Journal of Perinatology Reports, vol. 3, no. 1, pp. 45–50, 2013. View at Publisher · View at Google Scholar
  12. F. Jin, M. Cao, Y. Bai, Y. Zhang, Y. Yang, and B. Zhang, “Therapeutic effects of plasma exchange for the treatment of 39 patients with acute fatty liver of pregnancy,” Discovery Medicine, vol. 13, no. 72, pp. 369–373, 2012. View at Google Scholar · View at Scopus
  13. D. O. El-Haieg, M. F. Zanati, and F. M. El-Foual, “Plasmapheresis and pregnancy outcome in patients with antiphospholipid syndrome,” International Journal of Gynecology and Obstetrics, vol. 99, no. 3, pp. 236–241, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Frampton, J. S. Cameron, M. Thom, S. Jones, and M. Raftery, “Successful removal of anti-phospholipid antibody during pregnancy using plasma exchange and low-dose prednisolone,” The Lancet, vol. 2, no. 8566, pp. 1023–1024, 1987. View at Google Scholar · View at Scopus
  15. A. Bontadi, A. Ruffatti, P. Marson et al., “Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome,” Journal of Clinical Apheresis, vol. 27, no. 4, pp. 200–204, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Bortolati, P. Marson, S. Chiarelli et al., “Case reports of the use of immunoadsorption or plasma exchange in high-risk pregnancies of women with antiphospholipid syndrome,” Therapeutic Apheresis and Dialysis, vol. 13, no. 2, pp. 157–160, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Kobayashi, N. Tamura, H. Tsuda, C. Mokuno, H. Hashimoto, and S. Hirose, “Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy,” Annals of the Rheumatic Diseases, vol. 51, no. 3, pp. 399–401, 1992. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Ruffatti, P. Marson, V. Pengo et al., “Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature,” Autoimmunity Reviews, vol. 6, no. 3, pp. 196–202, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Ruffatti, E. Salvan, T. D. Del Ross et al., “Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study,” Thrombosis and Haemostasis, vol. 112, no. 4, pp. 727–735, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Bosch, “Therapeutic apheresis—state of the art in the year 2005,” Therapeutic Apheresis and Dialysis, vol. 9, no. 6, pp. 459–468, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Venkatesha, M. Toporsian, C. Lam et al., “Soluble endoglin contributes to the pathogenesis of preeclampsia,” Nature Medicine, vol. 12, pp. 642–649, 2006. View at Publisher · View at Google Scholar
  22. R. J. Levine, C. Lam, C. Qian et al., “Soluble endoglin and other circulating antiangiogenic factors in preeclampsia,” The New England Journal of Medicine, vol. 355, no. 10, pp. 992–1005, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Stepan, T. Krämer, and R. Faber, “Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 7, pp. 2831–2834, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Masuyama, H. Nakatsukasa, N. Takamoto, and Y. Hiramatsu, “Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in pre-eclampsia,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 7, pp. 2672–2679, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Jeyabalan, S. McGonigal, C. Gilmour, C. A. Hubel, and A. Rajakumar, “Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia,” Placenta, vol. 29, no. 6, pp. 555–563, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. A. De Vivo, G. Baviera, D. Giordano, G. Todarello, F. Corrado, and R. D'Anna, “Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia,” Acta Obstetricia et Gynecologica Scandinavica, vol. 87, no. 8, pp. 837–842, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. N. Kim, D. S. Lee, D. H. Jeong, M. S. Sung, and K. T. Kim, “The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia,” Prenatal Diagnosis, vol. 29, no. 5, pp. 464–470, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Reddy, S. Suri, I. L. Sargent, C. W. G. Redman, and S. Muttukrishna, “Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and pre-eclampsia,” PLoS ONE, vol. 4, no. 2, Article ID e4453, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Rana, S. A. Karumanchi, R. J. Levine et al., “Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia,” Hypertension, vol. 50, no. 1, pp. 137–142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. C. J. Robinson and D. D. Johnson, “Soluble endoglin as a second-trimester marker for preeclampsia,” American Journal of Obstetrics and Gynecology, vol. 197, no. 2, pp. 174.e1–174.e5, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. J. H. Lim, S. Y. Kim, SoYeonPark et al., “Soluble endoglin and transforming growth factor-β1 in women who subsequently developed preeclampsia,” Prenatal Diagnosis, vol. 29, no. 5, pp. 471–476, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Signore, J. L. Mills, C. Qian et al., “Circulating soluble endoglin and placental abruption,” Prenatal Diagnosis, vol. 28, no. 9, pp. 852–858, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. V. A. Rosenberg, I. A. Buhimschi, C. J. Lockwood et al., “Heparin elevates circulating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant women receiving anticoagulation therapy,” Circulation, vol. 124, no. 23, pp. 2543–2553, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Sela, S. Natanson-Yaron, E. Zcharia, I. Vlodavsky, S. Yagel, and E. Keshet, “Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase,” Circulation Research, vol. 108, no. 9, pp. 1063–1070, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Y. Carroll, M. J. Mulla, C. S. Han et al., “Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin,” American Journal of Reproductive Immunology, vol. 66, no. 4, pp. 286–296, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Yinon, E. Ben Meir, L. Margolis et al., “Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor,” Placenta, vol. 36, no. 2, pp. 121–124, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Cheifetz, T. Bellon, C. Cales et al., “Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells,” The Journal of Biological Chemistry, vol. 267, no. 27, pp. 19027–19030, 1992. View at Google Scholar
  38. S. St-Jacques, M. Forte, S. J. Lye, and M. Letarte, “Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy,” Biology of Reproduction, vol. 51, no. 3, pp. 405–413, 1994. View at Publisher · View at Google Scholar · View at Scopus
  39. U. Raab, B. Velasco, P. Lastres et al., “Expression of normal and truncated forms of human endoglin,” Biochemical Journal, vol. 339, no. 3, pp. 579–588, 1999. View at Publisher · View at Google Scholar · View at Scopus
  40. U. Raab, P. Lastres, M. A. Arévalo et al., “Endoglin is expressed in the chicken vasculature and is involved in angiogenesis,” FEBS Letters, vol. 459, no. 2, pp. 249–254, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. S. E. Duff, C. Li, J. M. Garland, and S. Kumar, “CD105 is important for angiogenesis: evidence and potential applications,” The FASEB Journal, vol. 17, no. 9, pp. 984–992, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Toporsian, R. Gros, M. G. Kabir et al., “A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia,” Circulation Research, vol. 96, no. 6, pp. 684–692, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Schwartz, J. L. Winters, A. Padmanabhan et al., “Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue,” Journal of Clinical Apheresis, vol. 28, no. 3, pp. 145–284, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Blaha, M. Cermanova, V. Blaha et al., “Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia,” Atherosclerosis, vol. 197, no. 1, pp. 264–270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. M. L. Schwartz, “Possible role for exchange plasmapheresis with fresh frozen plasma for maternal indications in selected cases of preeclampsia and eclampsia,” Obstetrics and Gynecology, vol. 68, no. 1, pp. 136–139, 1986. View at Google Scholar · View at Scopus
  46. J. N. Martin Jr., K. G. Perry Jr., W. E. Roberts et al., “Plasma exchange for preeclampsia: II. Unsuccessful antepartum utilization for severe preeclampsia with or without HELLP syndrome,” Journal of Clinical Apheresis, vol. 9, no. 3, pp. 155–161, 1994. View at Publisher · View at Google Scholar · View at Scopus
  47. A. J. F. d'Apice, L. L. Reti, R. J. Pepperell, K. F. Fairley, and P. Kincaid-Smith, “Treatment of severe pre-eclampsia by plasma exchange,” The Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 20, no. 4, pp. 231–235, 1980. View at Publisher · View at Google Scholar · View at Scopus